What is Xarelto?
Xarelto is the brand name of an oral blood-thinning drug with the generic name rivaroxaban. It is part of a new generation of anti-coagulant drugs intended to prevent deep vein thrombosis (DVT). DVT is a potentially fatal condition characterized by the formation of blood clots in veins, primarily in the legs, often after surgery like a hip or knee replacement or after an injury. DVT can be fatal if venous blood clots dislodge and travel to the lungs, creating a potentially lethal condition called pulmonary embolism (PE).
In July 2011, the U.S. Food and Drug Administration (FDA) approved the use of Xarelto for the prevention of DVT in patients receiving hip or knee replacements.
In November 2011, the FDA additionally approved Xarelto for the prevention of strokes in patients with non-valvular atrial fibrillation, a type of heart arrhythmia in patients who don’t have disease of the aortic or mitral valve. Strokes occur with the presence of blood clots on the brain.